Search for: "Janssen Research " Results 61 - 80 of 205
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Sep 2017, 5:00 am by melissalafreniere
However, the drug makers used flawed and unreliable research to get the drug on the market, says the Xarelto wrongful death lawsuit. [read post]
29 Aug 2017, 5:00 am by melissalafreniere
Manufacturer Janssen Research & Development, an arm of Johnson & Johnson Pharmaceutical Research and Development LLC is named in the lawsuit for allegedly marketing a dangerous drug without giving patients or doctors appropriate information about the serious side effects, including life-threatening bleeding from Xarelto that could result. [read post]
24 Aug 2017, 5:00 am by melissalafreniere
The lawsuit argues that defendants Janssen Research and Development, an arm of Johnson & Johnson, should have been aware of the severe side effects that put patients at risk. [read post]
10 Aug 2017, 2:35 pm by Tom Lamb
This New Medical Research Was Published Just Before "Black-Box Warning" About Lower Limb Amputations Added To Drug Labels   (Posted by Tom Lamb at DrugInjuryWatch.com)   In the final week of July 2017, the FDA issued a notification that it had approved a revised drug label for Invokana and Invokamet, as well as a revised Medication Guide for these two diabetes drugs from Janssen Pharmaceuticals. [read post]
8 Aug 2017, 8:49 pm by Scott
Frank Smart, the chief of cardiology and a professor of medicine at Louisiana State University School of Medicine, told jurors that he came to his conclusion based on a combination of his own research, internal company emails from Xarelto blood thinner manufacturers Janssen Pharmaceuticals and Bayer, and transcripts of Food and Drug Administration (FDA) reviewers’ opinions, legal industry website MasssTortNexus.com reported. [read post]
4 Aug 2017, 1:11 pm by Scott
A New York man has filed a lawsuit against Janssen Research & Development LLC, Bayer Healthcare Pharmaceuticals and related entities alleging he suffered uncontrolled Xarelto bleeding. [read post]
19 Jul 2017, 2:30 pm by Scott
A study published by University of British Columbia researchers found that males that took Risperdal or Invega were 69 percent more likely to develop man boobs than those who did not take the drugs. [read post]
18 Jul 2017, 2:55 pm by Scott
A 79-year-old man has filed a Xarelto lawsuit accusing Janssen Research and Development LLC, Johnson & Johnson and Bayer of concealing the risk of uncontrollable bleeding that is associated with the drug. [read post]
11 Jul 2017, 2:30 am by Kluwer UPC News blogger
According to research of IP Kat, and ‘if there are no further delays or unexpected hurdles, (…) it may be that the UK may have ratified the UPC by end of November/early December 2017’. [read post]
11 Jul 2017, 2:30 am by Kluwer UPC News blogger
According to research of IP Kat, and ‘if there are no further delays or unexpected hurdles, (…) it may be that the UK may have ratified the UPC by end of November/early December 2017’. [read post]
30 May 2017, 5:17 am by Howard Knopf
Janssen-Ortho Inc., 2009 FCA 212 (CanLII), where the need for explicit “acknowledgment” of the adoption of a party’s written submissions was addressed. [read post]
4 May 2017, 1:00 am by Jiao Yuxin
The clinical research of pharmaceutical polymorphs commenced in 1950s internationally though, it was until in mid-1990s did Chinese research institutions and pharmaceutical enterprises recognize the importance of pharmaceutical polymorphs after the first awareness of the significant efficacy difference between imported nimodipine and the homemade one. [read post]
21 Apr 2017, 6:25 am
Bulan, Cornerstone Research, on Tuesday, April 18, 2017 Tags: Accounting, Class actions, Derivative suits, Disclosure, Institutional Investors, Market reaction, Rule 10b-5, SEC, SEC enforcement, Section 11, Securities damages, Securities enforcement, Securities litigation, Securities regulation, Settlements Sustainability Matters: Focusing on your Future Today Posted by Elisse B. [read post]
21 Apr 2017, 6:25 am
Bulan, Cornerstone Research, on Tuesday, April 18, 2017 Tags: Accounting, Class actions, Derivative suits, Disclosure, Institutional Investors, Market reaction, Rule 10b-5, SEC, SEC enforcement, Section 11, Securities damages, Securities enforcement, Securities litigation, Securities regulation, Settlements Sustainability Matters: Focusing on your Future Today Posted by Elisse B. [read post]
13 Apr 2017, 11:48 am by Scott
Janssen Research & Development, LLC., et. al., Case No. 2:17-cv03777 in the U.S. [read post]
13 Apr 2017, 4:25 am by Adrien Alberini
Article 3 of the Proposal for a Directive provides for a new exception to copyright aimed at allowing researchers to benefit from a clearer legal space to use innovative text and data mining research tools, teachers and students to be able to take full advantage of digital technologies at all levels of education and cultural heritage institutions (i.e. publicly accessible libraries or museums, archives or film or audio heritage institutions) to be supported in their efforts to… [read post]